NCT06839755 The Positive Prognostic Value of Stress Echocardiography - AMPHIPOLIS STUDY
| NCT ID | NCT06839755 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hellenic Society of Cardiology |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 390 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 390 participants in total. It began in 2024-10-01 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multicenter, observational study of patients with recent stress echocardiography positive for myocardial ischemia. Up to now 25 echocardiography labs form Greece and Cyprus have declared their intention to participate. The investigators will enroll 390 patients with a positive stress echo, who will undergo invasive coronary angiogram and then will be followed up for at least 6 months. The objectives are the following: 1. To assess the prognostic value of positive stress echo by monitoring for cardiovascular death and major adverse cardiovascular events (MACE) during the follow-up. 2. To investigate the relationship of stress echo findings with invasive coronary angiography anatomical findings. 3. The association of cardiovascular risk profile of participants with stress echo and coronary angiography findings.
Eligibility Criteria
Inclusion Criteria: Patients with recent stress echocardiography positive for any extent of myocardial ischemia Exclusion Criteria: 1. HFrEF requiring viability study. 2. Any symptomatic valvular disease causing symptoms. 3. Established or suspected cardiomyopathy. 4. Concomitant chronic diseases reducing life expectancy (active cancer, severe liver impairment, auto-immune diseases etc). 5. Recent acute coronary syndrome the last week.
Contact & Investigator
Nikolaos Kadoglou
PRINCIPAL INVESTIGATOR
University of Cyprus
Frequently Asked Questions
Who can join the NCT06839755 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06839755 currently recruiting?
Yes, NCT06839755 is actively recruiting participants. Contact the research team at nikoskad@yahoo.com for enrollment information.
Where is the NCT06839755 trial being conducted?
This trial is being conducted at Athens, Greece.
Who is sponsoring the NCT06839755 clinical trial?
NCT06839755 is sponsored by Hellenic Society of Cardiology. The principal investigator is Nikolaos Kadoglou at University of Cyprus. The trial plans to enroll 390 participants.